LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

105.8 -1.41

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

104.2

Max

108.79

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.2M

-93M

Pardavimai

33M

265M

Pelno marža

-34.965

Darbuotojai

1,999

EBITDA

6.6M

-82M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+18.98% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

4.6B

14B

Ankstesnė atidarymo kaina

107.21

Ankstesnė uždarymo kaina

105.8

Naujienos nuotaikos

By Acuity

50%

50%

162 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-19 23:47; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-19 23:47; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

2026-02-19 23:39; UTC

Įsigijimai, susijungimai, perėmimai

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

2026-02-19 23:38; UTC

Uždarbis

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

2026-02-19 23:38; UTC

Uždarbis

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

2026-02-19 23:38; UTC

Uždarbis

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

2026-02-19 23:37; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Position Adjustment -- Market Talk

2026-02-19 23:34; UTC

Uždarbis

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

2026-02-19 23:34; UTC

Uždarbis

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

2026-02-19 23:33; UTC

Uždarbis

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

2026-02-19 23:33; UTC

Uždarbis

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

2026-02-19 22:13; UTC

Rinkos pokalbiai

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

2026-02-19 22:08; UTC

Uždarbis

Fairfax Financial 4Q Rev $8.11B >FFH.T

2026-02-19 22:07; UTC

Uždarbis

Eldorado Gold 4Q EPS $1.19 >ELD.T

2026-02-19 22:06; UTC

Uždarbis

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

2026-02-19 22:05; UTC

Uždarbis

Eldorado Gold 4Q Adj EPS 63c >ELD.T

2026-02-19 22:05; UTC

Uždarbis

Eldorado Gold 4Q Rev $577.2M >ELD.T

2026-02-19 22:04; UTC

Uždarbis

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

2026-02-19 22:04; UTC

Uždarbis

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

2026-02-19 21:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-02-19 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-19 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-02-19 21:43; UTC

Uždarbis

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

2026-02-19 21:42; UTC

Įsigijimai, susijungimai, perėmimai

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

2026-02-19 21:42; UTC

Uždarbis

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

2026-02-19 21:41; UTC

Uždarbis

Correct: St Barbara 1H Net Loss A$249,000

2026-02-19 21:40; UTC

Uždarbis

St Barbara 1H Net Loss A$249 Million

2026-02-19 21:39; UTC

Uždarbis

Perseus Mining Reaffirms FY26 Production, AISC Guidance

2026-02-19 21:37; UTC

Uždarbis

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

2026-02-19 21:37; UTC

Uždarbis

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

18.98% į viršų

12 mėnesių prognozė

Vidutinis 127.81 USD  18.98%

Aukščiausias 175 USD

Žemiausias 105 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

19

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

162 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat